StreetInsider.com News Articles

Form 6-K GH Research PLC For: May 21

Thu, 21 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26531333.html

Form 6-K GH Research PLC For: May 21

Thu, 21 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26531333.html

Form EFFECT GH Research PLC

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524312.html

Form EFFECT GH Research PLC

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524312.html

GH Research PLC (GHRS) PT Lowered to $65 at H.C. Wainwright

Tue, 19 May 2026 06:51:18 -0400

(Updated - May 19, 2026 6:51 AM EDT)

H.C. Wainwright analyst Patrick R. Trucchio lowered the price target on GH Research PLC (NASDAQ: GHRS) to $65.00 (from $70.00) while maintaining a Buy rating.

The analyst commented: "On May 14, GH Research reported 1Q26 results and a series of incremental updates that further de-risk the path toward initiation of the global Phase 3 trial evaluating GH001 in treatment-resistant depression (TRD) expected late 2026. Key developments include: (1) publication of the Phase 2b trial (GH001-TRD-201) results in JAMA Psychiatry, including a post-hoc analysis showing Day 8 remission rates of 53.9% to 63.6% across subgroups

GH Research PLC (GHRS) PT Lowered to $65 at H.C. Wainwright

Tue, 19 May 2026 06:51:18 -0400

(Updated - May 19, 2026 6:51 AM EDT)

H.C. Wainwright analyst Patrick R. Trucchio lowered the price target on GH Research PLC (NASDAQ: GHRS) to $65.00 (from $70.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A GH Research PLC Filed by: Lynx1 Capital Management LP

Mon, 18 May 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260518/26515759.html

Form SCHEDULE 13G/A GH Research PLC Filed by: Lynx1 Capital Management LP

Mon, 18 May 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260518/26515759.html

Form SCHEDULE 13G/A GH Research PLC Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506776.html

Form SCHEDULE 13G/A GH Research PLC Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506776.html

GH Research PLC (GHRS) PT Raised to $35 at Cantor Fitzgerald on Model Update

Fri, 15 May 2026 07:28:32 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on GH Research PLC (NASDAQ: GHRS) to $35.00 (from $25.00) while maintaining an Overweight rating.

The analyst commented, "We are updating our model to reflect reported earnings and increasing our outer-year adoption estimates for 001, driving our PT from $25 to $35 - reflecting increasing evolution of the psychiatry field to deliver an array of transformational psychedelic therapies. With a $1.5B mkt cap, we believe GHRS trades at <1x peak achievable sales for '001."

GH Research PLC (GHRS) PT Raised to $35 at Cantor Fitzgerald on Model Update

Fri, 15 May 2026 07:28:32 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on GH Research PLC (NASDAQ: GHRS) to $35.00 (from $25.00) while maintaining an Overweight rating.

Canaccord Reiterates Buy Rating on GH Research PLC (GHRS)

Fri, 15 May 2026 06:36:36 -0400

Canaccord analyst Sumant Kilkami reiterated a Buy rating and $39.00 price target on GH Research PLC (NASDAQ: GHRS).

The analyst commented: "GHRS reported its 1Q26 results earlier today (5/14). Operating expenses of $18.7mn were essentially in line with our $19.0mn estimate. The key updates for us were that GHRS has selected its doses for a global Phase 3 pivotal program. Importantly, the company reiterated its intent to seek FDA alignment on Phase 3 trial design for GH001 (inhaled mebufotenin or 5-MeO-DMT) for treatment-resistant depression (TRD), and remains on track to start a global Phase 3 program in late 2026. Separately, with

GH Research PLC (GHRS) PT Lowered to $39 at Citizens on Recent Equity Financing

Fri, 15 May 2026 05:00:23 -0400

Citizens analyst Jason Butler lowered the price target on GH Research PLC (NASDAQ: GHRS) to $39.00 (from $42.00) while maintaining a Market Outperform rating.

The analyst commented, "Pivotal GH001 trial to initiate in late 2026; we reiterate our Market Outperform rating on GH Research but decrease our risk-adjusted, DCF-derived price target to $39 from $42 to reflect the recent equity financing. This morning, GH Research reported 1Q26 financial results and business updates highlighting continued progress with the GH001 development program. Management reiterated timelines to initiate the pivotal trial in late 2026 and continues to engage with the FDA on Phase 3

GH Research PLC (GHRS) PT Lowered to $39 at Citizens on Recent Equity Financing

Fri, 15 May 2026 05:00:23 -0400

Citizens analyst Jason Butler lowered the price target on GH Research PLC (NASDAQ: GHRS) to $39.00 (from $42.00) while maintaining a Market Outperform rating.

Form 6-K GH Research PLC For: May 14

Thu, 14 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26495690.html

Form 6-K GH Research PLC For: May 14

Thu, 14 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26495690.html

GH Research (GHRS) files $400M mixed shelf

Thu, 14 May 2026 09:22:22 -0400

GH Research (NASDAQ: GHRS) has filed $400,000,000 mixed shelf of:

Ordinary Shares
Debt Securities
Warrants
Units
Subscription Rights

GH Research (GHRS) files $400M mixed shelf

Thu, 14 May 2026 09:22:22 -0400

GH Research (NASDAQ: GHRS) has filed $400,000,000 mixed shelf of:

Ordinary Shares
Debt Securities
Warrants
Units
Subscription Rights

Form F-3 GH Research PLC

Thu, 14 May 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260514/26491371.html

Form F-3 GH Research PLC

Thu, 14 May 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260514/26491371.html

GH Research enters $200 million at-the-market equity offering agreement

Thu, 14 May 2026 09:12:12 -0400

GH Research (NASDAQ: GHRS) entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company on May 14, 2026, according to a company statement.

Under the agreement, GH Research may offer and sell up to $200 million of its ordinary shares through Stifel, which will act as sales agent or principal. The shares have a nominal value of $0.025 per share.

The sales will be conducted from time to time under a prospectus supplement and accompanying prospectus, the company stated.

GH Research enters $200 million at-the-market equity offering agreement

Thu, 14 May 2026 09:12:12 -0400

GH Research (NASDAQ: GHRS) entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company on May 14, 2026, according to a company statement.

The sales will be conducted from time to time under a prospectus supplement and accompanying prospectus, the company stated.

Form 424B5 GH Research PLC

Thu, 14 May 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26491163.html

Form 424B5 GH Research PLC

Thu, 14 May 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26491163.html